Crestchem revenue up 18% but profit flat at ₹2.71 cr

Tipsheet Editorial — Fri, 19 Jun 2026 18:36:15 GMT

Revenue grew to ₹29.61 crore in FY26, but net profit stayed virtually unchanged at ₹2.71 crore. Board recommends ₹1.50 dividend per share.

What’s new

Revenue grew 18% to ₹29.61 cr, but net profit flat at ₹2.71 cr vs ₹2.73 cr last year.
Board recommends final dividend of ₹1.50 per share for the year.
Formally approved ₹2.25 cr investment in subsidiary Oleo Biosciences, previously disclosed.

Why it matters

For a debt-free nano-cap with 36.5% ROE, a stagnant profit on higher revenue suggests margin compression. The dividend offers a modest return, while the biosciences investment is a small but strategic bet.

What we’re watching

Whether margin pressure eases in H1 FY27 or continues.
Progress at Oleo Biosciences and its impact on future growth.
Scope for higher dividends given strong cash generation.

The full read

Crestchem's FY26 numbers show a familiar pattern: revenue up 18% to ₹29.61 crore, but profit stuck at ₹2.71 crore — almost identical to last year's ₹2.73 crore. That's margin compression in plain sight. For a debt-free nano-cap with 36.5% ROE, every rupee of extra revenue getting eaten by costs is the one number to track. The ₹2.25 crore investment in Oleo Biosciences and the ₹1.50 dividend were already baked in. The margin squeeze makes FY27 the test of whether Crestchem can turn top-line growth into bottom-line gains.

Primary source: BSE · NSE

Crestchem's FY26 revenue rises 18% but profit flat

Tipsheet Editorial — Fri, 19 Jun 2026 16:35:05 GMT

Net profit nearly unchanged at ₹2.71 cr on revenue of ₹29.61 cr. Board recommends ₹1.50 dividend and formalizes ₹2.25 cr subsidiary investment.

What’s new

FY26 revenue rose 18% to ₹29.61 crore, but net profit stayed flat at ₹2.71 crore.
Board recommended a final dividend of ₹1.50 per share.
Approved ₹2.25 crore capital commitment in subsidiary Oleo Biosciences, a previously disclosed investment.

Why it matters

For a nano-cap with a market cap of ₹42 crore, profit stagnation despite solid revenue growth is a sign of margin compression. The dividend is modest, and the subsidiary investment was already known, so this filing contains no market-moving news.

What we’re watching

Whether margin pressure persists into FY27.
How the ₹2.25 crore investment in Oleo Biosciences contributes to future earnings.
Any update on the utilization of the dividend payout.

The full read

Crestchem's top line grew 18% to ₹29.61 crore for FY26, but net profit barely moved: ₹2.71 crore against ₹2.73 crore the prior year. The board recommended a final dividend of ₹1.50 per share and formally approved a ₹2.25 crore capital commitment in subsidiary Oleo Biosciences. That decision was already disclosed, so no surprise. The investment is material at ≈5.4% of market cap (₹42 crore), but the lack of novelty makes this a routine update. Profit didn't budge despite the revenue jump, a point to watch next year.

Primary source: BSE · NSE

Crestchem Ltd. (CRSTCHM) — Tipsheet

Crestchem revenue up 18% but profit flat at ₹2.71 cr

What’s new

Why it matters

What we’re watching

The full read

Crestchem's FY26 revenue rises 18% but profit flat

What’s new

Why it matters

What we’re watching

The full read